Komo

CRISPR Therapeutics

Who are CRISPR Therapeutics's decision-makers?

CRISPR Therapeutics's official leadership and governance pages are the safest source for named executives.

Primary buyers
Finance, procurement, IT, security, operations, legal, and business leadership
Company status
Public company; Nasdaq: CRSP
HQ
Zug, Switzerland
Category
Gene editing therapeutics company
Decision style
Public-company buying committee
Best source
Official leadership or IR page
  • CRISPR Therapeutics executive leadershipExecutive leadership teamCurrent as of June 2026Use the official leadership, governance, or investor-relations page for current named executives before outreach.
  • CRISPR Therapeutics finance leadershipFinance / CFO organizationCurrent as of June 2026Often owns investor communication, procurement governance, capital allocation, and budget discipline.
  • CRISPR Therapeutics operations or technology leadershipOperations, product, technology, security, or commercial leadershipCurrent as of June 2026Likely stakeholder group for software, infrastructure, data, workflow, and operating-improvement purchases.

Who leads CRISPR Therapeutics?

CRISPR Therapeutics's named leaders should be verified directly on the company's official leadership, governance, or investor-relations page.

Who owns buying decisions at CRISPR Therapeutics?

The buying committee depends on the offer and usually spans finance, procurement, legal, IT/security, and the business owner.

How should sellers map the account?

Start with headquarters and public leadership, then map functional owners by product area, job posts, filings, partner announcements, and investor materials.

As of June 2026.Sources:CRISPR Therapeutics official websiteCRISPR Therapeutics investor relations or company newsBuiltWith public technology profile

CRISPR Therapeutics — frequently asked questions

Agent CTA Background

Revenue work. On autopilot.

Start Free TrialBuilt for revenue teams who care about quality.